4

PRIMARY DOCUMENT

Company: ENDONOVO THERAPEUTICS, INC.
Filed: February 21, 2019
Period of Report: February 14, 2019
Accession Number: 0001645470-19-000012

View Document ↗ View on SEC.gov ↗